For US residents only.


The first FDA-approved CAR-T cell therapy for patients up to 25 years old with second or later relapse or refractory B-cell ALL

Important Safety Information, including Boxed WARNING:

KYMRIAH may cause side effects that are severe or life-threatening. Call your health care provider or get emergency help right away if you have any of the following:

  • difficulty breathing
  • fever (100.4°F/...

See More
Approved Uses:

What is KYMRIAH?

KYMRIAH™ (tisagenlecleucel) is a prescription cancer treatment used in patients up to 25 years old who have acute lymphoblastic leukemia (ALL) that is either relapsing (went into remission, then came back) or refractory (did not go into remission with other leukemia tr...

See More
learn more about

Treatment Information

KYMRIAH™ (tisagenlecleucel) is a new therapy for pediatric and young adult patients with relapsed/refractory B-cell ALL.

Learn More
learn more about

Where to Get Treatment

KYMRIAH is available at select treatment centers across the United States. Click below to find the location nearest to you.

Learn More